TFS Acquires US Oncology and Vaccine Specialist Beardsworth Consulting Group, Inc.
On April 26th, 2013, TFS International (TFS) has completed the acquisition of the New Jersey based
Oncology and Vaccine specialist Contract Research Organization (CRO), Beardsworth Consulting Group, Inc. (BCG).
In a move to expand its oncology and vaccine research services, TFS has announced the completion of acquiring BCG,
an independent clinical CRO with headquarters in Flemington, New Jersey, and with clinical research professionals
located throughout North America. BCG was established by Ms. Donna Beardsworth in 1986 and, through her commitment
to clinical research and entrepreneurship, BCG became a recognized and trusted industry leader in the execution of
complex clinical trials within oncology, vaccines, and other important therapeutic areas.
The acquisition of BCG follows the TFS global strategy to grow its North American operations to 600 professionals
with comparable capabilities and expertise to its existing European business. The BCG acquisition will complement
TFS’ competences in oncology and vaccines, among several others therapeutics areas, as well as provide scalable
operational resources throughout North America. BCG’s operations include comprehensive clinical research services
together with project management and monitoring across all study phases, data management, biostatistics, regulatory
consulting, and medical writing.
"The BCG deal is really a welcomed component in the strategic vision of TFS. It adds competencies in active and
growing therapeutic areas, increases our operational capabilities in North America and expands substantially our customer
portfolio of smaller and midsized life science companies in one of the most important global research markets. It aligns
very well with where we want to be as a company," said Mr. Daniel Spasic, Chief Executive Officer at TFS.
TFS has recently completed several acquisitions and the BCG deal follows two other transactions in the last five
months, including the acquisition of Dimensione Ricerca in Italy and the technology provider for Electronic Data
Capture (EDC) services, Semcon in Sweden.
"We are very pleased to have found a global partner through the TFS Group. TFS and BCG share a common culture of quality
and professional service of the highest caliber. As a combined operation, we now have significant resources deployed across
multiple continents. It is rewarding to know that our global capabilities will now provide considerable value to our clients,
and the patients that we ultimately serve. I have the highest confidence that the combined TFS/BCG team will create true synergies
and material benefit to the biopharmaceutical industry, under the TFS name" said Mr. Doug Beardsworth, Executive Chairman at BCG.
TFS and BCG have had a history of collaboration on several global clinical programs in oncology and other therapeutic areas.
Operational processes and quality systems have been well established which will facilitate an efficient integration between the
two groups as well as ensuring business continuity and focus on the ongoing clinical projects and customers.
"Mr. Hani Zaki will be taking the helm for the TFS US organization as the Executive VP and President Americas. He is a seasoned
and trusted pharmaceutical and CRO executive who has spent many years working for public and private CROs, and is a well-respected
professional within the life science community," said Mr. Spasic.
The terms and conditions of the acquisition have not been disclosed.
Click here for contact information. Click the TFS logo below to visit the TFS website.
Click here for employment opportunities.
Click here to be added to our Investigator Database.